EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Feasibility of using a combination of staphylococcal superantigen‐like proteins 3, 7 and 11 in a fusion vaccine for Staphylococcus aureus

Janlin Ying Hui Chan, Fiona Clow, Victoria Pearson, Ries J Langley iD, John D Fraser, Fiona J Radcliff iD

Immunology & Cell Biology · 2024

DOI: 10.1111/imcb.12745 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Immunology & Cell Biology, 2024. Verfasst von Janlin Ying Hui Chan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Medicine and Pathology, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand. Hauptthemen laut MEDLINE: Staphylococcus aureus, Staphylococcal Vaccines, Superantigens, Staphylococcal Infections. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Health Research Council of New Zealand.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Staphylococcus aureus is a significant bacterial pathogen in both community and hospital settings, and the escalation of antimicrobial‐resistant strains is of immense global concern. Vaccination is an inviting long‐term strategy to curb staphylococcal disease, but identification of an effective vaccine has proved to be challenging. Three well‐characterized, ubiquitous, secreted immune evasion factors from the staphylococcal superantigen‐like (SSL) protein family were selected for the development of a vaccine. Wild‐type SSL3, 7 and 11, which inhibit signaling through Toll‐like receptor 2, cleavage of complement component 5 and neutrophil function, respectively, were successfully combined into a stable, active fusion protein (PolySSL7311). Vaccination of mice with an attenuated form of the PolySSL7311 protein stimulated significantly elevated specific immunoglobulin G and splenocyte proliferation responses to each component relative to adjuvant‐only controls. Vaccination with PolySSL7311, but not a mixture of the individual proteins, led to a > 10 2 reduction in S. aureus tissue burden compared with controls after peritoneal challenge. Comparable antibody responses were elicited after coadministration of the vaccine in either AddaVax (an analog of MF59) or an Alum‐based adjuvant; but only AddaVax conferred a significant reduction in bacterial load, aligning with other studies that suggest both cellular and humoral immune responses are necessary for protective immunity to S. aureus . Anti‐sera from mice immunized with PolySSL7311, but not individual proteins, partially neutralized the functional activities of SSL7. This study confirms the importance of these SSLs for the survival of S. aureus in vivo and suggests that PolySSL7311 is a promising vaccine candidate.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Staphylococcus aureusStaphylococcal VaccinesSuperantigensStaphylococcal InfectionsBacterial ProteinsAnimalsMiceAntibodies, BacterialFemaleRecombinant Fusion ProteinsImmunoglobulin GFeasibility StudiesVaccinationAntigens, BacterialMice, Inbred BALB CAdjuvants, Immunologic

Stichwörter der Autor:innen

Neutralizing antibodyS. aureusperitoneal infectionprotectionstaphylococcal superantigen‐likevaccine

Substanzen

Staphylococcal VaccinesSuperantigensBacterial ProteinsAntibodies, BacterialRecombinant Fusion ProteinsImmunoglobulin GAntigens, BacterialAdjuvants, Immunologic

Autor:innen und Institutionen

  • Department of Molecular Medicine and Pathology, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.

ORCID-Profile: Ries J Langley, Fiona J Radcliff

Förderung

  • Health Research Council of New Zealand

Zitieren

APA

Chan, J. Y. H., Clow, F., Pearson, V., Langley, R. J., Fraser, J. D., & Radcliff, F. J. (2024). Feasibility of using a combination of staphylococcal superantigen‐like proteins 3, 7 and 11 in a fusion vaccine for Staphylococcus aureus. Immunology & Cell Biology. https://doi.org/10.1111/imcb.12745

Vancouver

Chan JYH, Clow F, Pearson V, Langley RJ, Fraser JD, Radcliff FJ. Feasibility of using a combination of staphylococcal superantigen‐like proteins 3, 7 and 11 in a fusion vaccine for Staphylococcus aureus. Immunology & Cell Biology. 2024. doi:10.1111/imcb.12745

BibTeX
@article{Chan2024,
  author = {Chan, Janlin Ying Hui and Clow, Fiona and Pearson, Victoria and Langley, Ries J and Fraser, John D and Radcliff, Fiona J},
  title = {Feasibility of using a combination of staphylococcal superantigen‐like proteins 3, 7 and 11 in a fusion vaccine for Staphylococcus aureus},
  journal = {Immunology & Cell Biology},
  year = {2024},
  doi = {10.1111/imcb.12745}
}
Kostenlos starten →